EU squabbles over medical device rules; Verinata teams with Teva for prenatal Dx;

 @FierceMedDev: Veracyte nails $28M Series C. Story | Follow @FierceMedDev

 @MarkHFierce: There's still time to submit your nomination for this year's FMD Fierce 15. More | Follow @MarkHFierce

 @DamianFierce: Thoratec is spending up to $56.5M for Terumo's in-development heart device. News | Follow @DamianFierce

> Politicians and industry leaders in the European Union remain divided about how to update their regulatory system for medical devices. Story

> Illumina ($ILMN) won a CE mark for its MiSeqDx cystic fibrosis system, gearing up to market the next-generation sequencing instrument and its assays in Europe. News

> OrthoFix ($OFIX) has launched its Trinity Elite spinal fixation technology in the U.S. Release

> Verinata Health, recently acquired by Illumina, has teamed up with Teva Pharmaceutical Industries ($TEVA) to market its Verifi prenatal diagnostic test in Israel. More

> 2012 Fierce 15 winner T2 Biosystems notched positive data for its T2Hemostat diagnostic, finding that its test accurately correlated to 100% of bleeding events in a study of 26 patients. Item

> MDxHealth ($MDXH) has partnered with Summit Pharmaceuticals to get its epigenetic diagnostics products into Japan. Report

> Silver, which is often added to medical devices to prevent bacteria from sticking, may actually end up accelerating the problem rather than stopping it. Story

Biotech News

 @FierceBiotech: Insmed shares routed on head-to-head antibiotic Phase III results. Story | Follow @FierceBiotech

 @JohnCFierce: The FDA's suvorexant decision was expected. I don't see how weak suvo competes with the generics. It'll be an alternative for non-response. | Follow @JohnCFierce

 @RyanMFierce: Onyx is following the M&A resistance strategy, which Termeer and more recently Martin have used. More | Follow @RyanMFierce

> FDA scraps Merck's high-dose sleep drug, demands weaker version. Story

> Report: China rounds up GlaxoSmithKline staffers in corruption probe. Article

Pharma News

 @FiercePharma: Fresenius Kabi yanks four lots of benztropine mesylate on risk of glass particles, stops distribution to investigate. News | Follow @FiercePharma

 @EricPFierce: ICYMI: FDA approves first non-hormonal treatment for hot flashes. Release | Follow @EricPFierce

> Merck KGaA sees U.S. as "emerging market" for sales growth. More

> Pfizer, Bristol-Myers tout new VTE data on Eliquis, aiming for new use. News

CRO News

> MMS teams up with Datatrak for eClinical heft. Story

> Want to work with Roche? Prepare for high standards. More

> AstraZeneca taps Sarah Cannon for cancer R&D. Article

Biotech IT News

> Ex-Googlers bring Big Data analytics to oncology. News

> Deloitte turns EHR reservoir into health outcomes tool. Article

> J&J teams up with Mount Sinai on bioinformatics project. Story

> Data secrecy and outdated tech exacerbating drug shortages. More

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.